BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 15, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xiapex regulatory update

Auxilium disclosed in its 2Q11 earnings that Swissmedic approved Xiapex collagenase clostridium histolyticum to treat Dupuytren's contracture in adult patients with a palpable cord. Pfizer Inc. (NYSE:PFE,...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >